The Oncosearch | Oncotarget

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling Research Perspective

Jordan L. Kohlmeyer, David J. Gordon, Munir R. Tanas, Rebecca D. Dodd, Varun Monga, Benjamin W. Darbro, Dawn E. Quelle

Published Dec 26, 2020 · Vol. 12, No. 1 · pp. 10-14

Keywords: MPNST, RABL6A-RB1 signaling, CDK4/6 and MEK inhibitors, Ras, targeted cancer therapy

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020 · Vol. 11, No. 46 · pp. 4201-4223

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

Michael E. Clark, Helen Rizos, Michelle R. Pereira, Ashleigh C. McEvoy, Gabriela Marsavela, Leslie Calapre, Katie Meehan, Olivia Ruhen, Muhammad A. Khattak, Tarek M. Meniawy, Georgina V. Long, Matteo S. Carlino, Alexander M. Menzies, Michael Millward, Melanie Ziman, Elin S. Gray

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 4016-4027

Keywords: melanoma, targeted therapy, drug resistance, BRAF splicing, extracellular vesicles

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

Douglas B. Johnson, Caroline A. Nebhan, Marcus S. Noel

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 3900-3903

Keywords: trametinib, MEK, BRAF, atypical, fusion

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

Published Oct 7, 2020 · Vol. 11, No. 44 · pp. 3984-3997

Keywords: pan-RAF inhibitor, Bim, FOXO3a, bortezomib, lenalidomide

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver, Matthew B. Soellner

Published Oct 3, 2020 · Vol. 11, No. 44 · pp. 3921-3932

Keywords: bladder cancer, drug screen, 3D culture, basal bladder cancer, MEK inhibition

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

Matteo Torresetti, Donatella Brancorsini, Francesca Morgese, Valeria Cognigni, Alessandro Scalise, Rossana Berardi, Giovanni Di Benedetto

Published Jul 30, 2020 · Vol. 11, No. 34 · pp. 3256-3262

Keywords: sarcomatoid melanoma, giant melanoma, BRAF mutation, targeted therapy, next-generation sequencing

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper

Oliver J. Pickles, Aneta Drozd, Louise Tee, Andrew D. Beggs, Gary W. Middleton

Published Jul 13, 2020 · Vol. 11, No. 34 · pp. 3188-3197

Keywords: colorectal cancer, BRAF, paradox breaker, encorafenib, PLX8394

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Mara W. Rosenberg, Kevin Watanabe-Smith, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker, Uma Borate

Published Jun 17, 2020 · Vol. 11, No. 29 · pp. 2807-2818

Keywords: acute myeloid leukemia, drug sensitivity, midostaurin, drug resistance, FLT3

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Tomoya Aikawa, Noriko Togashi, Koichi Iwanaga, Hiroyuki Okada, Yumi Nishiya, Shinichi Inoue, Mark J. Levis, Takeshi Isoyama

Published Mar 17, 2020 · Vol. 11, No. 11 · pp. 943-955

Keywords: relapsed/refractory AML, FLT3 inhibitors, quizartinib, AC886, midostaurin resistance

Thymoquinone induces apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer stem/progenitor cells Research Paper

Farah Ballout, Alissar Monzer, Maamoun Fatfat, Hala El Ouweini, Miran A. Jaffa, Rana Abdel-Samad, Nadine Darwiche, Wassim Abou-Kheir, Hala Gali-Muhtasib

Published Jan 3, 2020 · Vol. 11, No. 31 · pp. 2959-2972

Keywords: thymoquinone, colorectal cancer stem cells, 5-Fluorouracil resistance, colonospheres, apoptosis

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Errata

Amanda M. Smith, Christine R.C. Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink, Andrew S. Moore

Published Dec 18, 2019 · Vol. 11, No. 3 · pp. 305-305

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

Thomas B. Davis, Mingli Yang, Heiman Wang, Changgong Lee, Timothy J. Yeatman, W. Jack Pledger

Published Nov 26, 2019 · Vol. 10, No. 63 · pp. 6768-6780

Keywords: colorectal cancer, PTPRS, ERK, SRC, adaptive resistance

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Rowland H. Han, Gavin P. Dunn, Milan G. Chheda, Albert H. Kim

Published Nov 19, 2019 · Vol. 10, No. 62 · pp. 6739-6753

Keywords: brain metastases, targeted therapy, precision medicine, immunotherapy, systemic therapy

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper

Alexander K. Verma, Shanta M. Messerli, W. Keith Miskimins

Published Nov 15, 2019 · Vol. 11, No. 17 · pp. 1493-1504

Keywords: oropharyngeal cancer, lactate, Ras, anti-tumor immunity, PD-L1

The multifaceted anti-cancer effects of BRAF-inhibitors Review

Laura Croce, Francesca Coperchini, Flavia Magri, Luca Chiovato, Mario Rotondi

Published Nov 12, 2019 · Vol. 10, No. 61 · pp. 6623-6640

Keywords: BRAF, BRAF-inhibitors, tumor microenvironment, chemokines, CXCL8

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

Sean M. Flynn, Jacqueline Lesperance, Andrew Macias, Nikki Phanhthilath, Megan Rose Paul, Jong Wook Kim, Pablo Tamayo, Peter E. Zage

Published Oct 29, 2019 · Vol. 10, No. 59 · pp. 6323-6333

Keywords: neuroblastoma, RXDX-105, CEP-32496, RET, BRAF

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Research Paper

Amanda M. Smith, Christine R.C. Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink, Andrew S. Moore

Published Oct 8, 2019 · Vol. 10, No. 56 · pp. 5755-5767

Keywords: myeloid leukemia, therapy, drug resistance, hematological malignancies, gene mutation

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Kwang Woon Kim, Julia Y. Kim, Jingbo Qiao, Rachael A. Clark, Camille M. Powers, Hernan Correa, Dai H. Chung

Published Sep 24, 2019 · Vol. 10, No. 54 · pp. 5645-5659

Keywords: chemotherapy, radiotherapy, resistance, AKT2, MAPK

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling Research Perspective

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

MEK is a promising target in the basal subtype of bladder cancer Research Paper

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Thymoquinone induces apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer stem/progenitor cells Research Paper

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Errata

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper

The multifaceted anti-cancer effects of BRAF-inhibitors Review

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Research Paper

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling Research Perspective

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

MEK is a promising target in the basal subtype of bladder cancer Research Paper

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients Research Paper

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells Research Paper

Thymoquinone induces apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer stem/progenitor cells Research Paper

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Errata

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma Research Paper

The multifaceted anti-cancer effects of BRAF-inhibitors Review

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo Research Paper

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Research Paper

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma Research Paper

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper